Forward P/S Multiple: InMode (INMD)

InMode Ltd. - graphic logo of issuer INMD

The expected P/S ratio demonstrates a trend where 1.90 records a new level. Aggressive sales and high bonuses for B2B specialists support this growth. High profitability allows InMode Ltd. (INMD) to maintain its staff of Israeli development engineers. Business efficiency is based on strict cost control and the regular release of innovative radiofrequency devices for aesthetic medicine.

inmodemd.com - INMD Market Cap to Projected Revenue (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for InMode MD (INMD)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Fundamental company analysis:INMD (InMode)
Product sample of InMode MD

InMode Ltd. is transforming aesthetic medicine through minimally invasive radiofrequency technologies, which directly impacts expected sales dynamics. The forward P/S ratio compares the current market value of the business with projected annual revenue, revealing whether the asset is overvalued or undervalued. This indicator measures market expectations, allowing investors to identify entry points when multiples are depressed. The history of forward P/S changes helps synchronize capitalization with the actual pace of innovation expansion.

Who InMode Ltd. competes with

Price-to-Projected Revenue Ratio Dexcom DXCM|PEN - Forward Price-to-Revenue Multiple|Novanta Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Haemonetics Company|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED) - Forward P/S Multiple|Pulse Biosciences Inc (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple PMI|Forward Price-to-Revenue Multiple Surmodics Inc. SRDX|Forward P/S Multiple SENS (Senseonics Holdings)|Forward P/S Multiple neuropace.com NPCE|TCMD - Price-to-Projected Revenue Ratio|SNWV: Price-to-Projected Revenue Ratio|OM (Outset) - Forward Price-to-Revenue Multiple|Electromed - Forward Price to Sales|LNSR (LENSAR, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio avitamedical.com RCEL|Price-to-Projected Revenue Ratio Profound Medical Corp. (PROF)|bairdmed.com (BDMD) - Projected Price to Revenue|EDAP TMS - Forward Price-to-Revenue Multiple|Forward P/S Multiple Apyx Medical Corp APYX|IceCure Medical, Ltd. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Pulmonx Corporation LUNG|telabio.com (TELA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CTSO (CytoSorbents Corporation)|Price-to-Projected Revenue Ratio Sensus Healthcare Corp|Forward Price-to-Revenue Multiple Zynex Corp (ZYXI)|Forward P/S Multiple ECOR|RBOT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Inspira Technologies IINN|ICU: Market Cap to Projected Revenue|IRIX: Forward Price-to-Revenue Multiple|Intelligent Bio Solutions - Price to Expected Revenue Ratio|XAIR: Forward P/S Multiple|PFSA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio STRATA Skin Sciences Inc.|Market Cap to Projected Revenue GCTK (glucotrack.com)|Price-to-Projected Revenue Ratio NanoVibronix (NAOV)|Forward Price-to-Revenue Multiple Venus Concept Corporation VERO|Price-to-Projected Revenue Ratio Nuwellis, Inc. NUWE|aethlonmedical.com (AEMD) - Market Cap to Future Revenue Ratio|TransEnterix - Forward P/S Multiple|AVGR (Avinger Inc.) - Market Cap to Projected Revenue|BSGM: Forward P/S Multiple|Market Cap to Future Revenue Ratio Cutera Inc (CUTR)|Forward Price-to-Revenue Multiple KNW|NARI: Forward Price to Sales|Price-to-Projected Revenue Ratio Nevro (NVRO)|Price-to-Projected Revenue Ratio RSLS (reshapelifesciences.com)|Silk Road Medical Inc. - Forward Price-to-Revenue Multiple